Curyx Bio


Innovation Toward First-in-Class Drugs

Curyx Bio, Inc. is a biopharmaceutical company developing novel drugs for neurodegenerative disorders, inborn errors of metabolism, and autoimmune disorders using a variety of tools including orally available small molecule, intranasal peptide, recombinant protein, and monoclonal antibody.

With the passion to cure patients using unique therapeutic interventions, we aim at developing first-in-class drugs.

Curyx Bio is developing unique first-in-class drugs based on solid science.

Curyxbio Team